Testing bronchodilator responsiveness

Christer Janson^{1

2}, Andrei Malinovschi³, Andre F S Amaral², Simone Accordini⁴, Jean Bousquet^{5

6

7}, A Sonia Buist⁸, Judith Garcia-Aymerich^{9

10

11}, Louisa Gnatiuc¹², Wan Tan¹³, Kjell Torén¹⁴, Torsten Zuberbier⁷, Peter Burney²; all the authors

Affiliations

¹ Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
² Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK.
³ Dept of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.
⁴ Unit of Epidemiology and Medical Statistics, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy.
⁵ Fondation FMC VIA-LR, Montpellier, France.
⁶ Euforea, Brussels, Belgium.
⁷ Allergy Centre Charité, Dept of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁸ Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.
⁹ ISGlobal, Barcelona, Spain.
¹⁰ Universitat Pompeu Fabra (UPF), Barcelona, Spain.
¹¹ CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
¹² Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Dept of Population Health, University of Oxford, Oxford, UK.
¹³ Centre for Heart Lung Innovation (Tan, Sin), University of British Columbia, St. Paul's Hospital Vancouver, Vancouver, BC, Canada.
¹⁴ Dept of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden.

PMID: 31801819
DOI: 10.1183/13993003.02104-2019

Comment

Testing bronchodilator responsiveness

Christer Janson et al. Eur Respir J. 2019.

. 2019 Dec 4;54(6):1902104.

doi: 10.1183/13993003.02104-2019. Print 2019 Dec.

Authors

Affiliations

¹ Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
² Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College London, London, UK.
³ Dept of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden.
⁴ Unit of Epidemiology and Medical Statistics, Dept of Diagnostics and Public Health, University of Verona, Verona, Italy.
⁵ Fondation FMC VIA-LR, Montpellier, France.
⁶ Euforea, Brussels, Belgium.
⁷ Allergy Centre Charité, Dept of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁸ Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.
⁹ ISGlobal, Barcelona, Spain.
¹⁰ Universitat Pompeu Fabra (UPF), Barcelona, Spain.
¹¹ CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
¹² Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Dept of Population Health, University of Oxford, Oxford, UK.
¹³ Centre for Heart Lung Innovation (Tan, Sin), University of British Columbia, St. Paul's Hospital Vancouver, Vancouver, BC, Canada.
¹⁴ Dept of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden.

PMID: 31801819
DOI: 10.1183/13993003.02104-2019

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Janson has nothing to disclose. Conflict of interest: A. Malinovschi has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose. Conflict of interest: S. Accordini has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees and other funding from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and other funding from Kyomed, outside the submitted work. Conflict of interest: A.S. Buist has nothing to disclose. Conflict of interest: J. Garcia-Aymerich has nothing to disclose. Conflict of interest: L. Gnatiuc has nothing to disclose. Conflict of interest: W. Tan has nothing to disclose. Conflict of interest: K. Torén has nothing to disclose. Conflict of interest: T. Zuberbier has received consultancy fees from Bayer Health Care, FAES, Novartis and Henkel; has received grants/has grants pensing form Novartis and Henkel, and has received lecture fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer HealthCare, Bencradm Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, TEVA, UCB, Henkel, Kryolan and L'Oreal, outside the submitted work. Conflict of interest: P. Burney has nothing to disclose.

Comment on

Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
Janson C, Malinovschi A, Amaral AFS, Accordini S, Bousquet J, Buist AS, Canonica GW, Dahlén B, Garcia-Aymerich J, Gnatiuc L, Kowalski ML, Patel J, Tan W, Torén K, Zuberbier T, Burney P, Jarvis D. Janson C, et al. Eur Respir J. 2019 Sep 5;54(3):1900561. doi: 10.1183/13993003.00561-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31221806
Testing bronchodilator responsiveness.
Miller MR. Miller MR. Eur Respir J. 2019 Dec 4;54(6):1902036. doi: 10.1183/13993003.02036-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31801818 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

G0901214/MRC_/Medical Research Council/United Kingdom

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Testing bronchodilator responsiveness

Affiliations

Testing bronchodilator responsiveness

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

Grants and funding